Kymera Therapeutics, Inc.

NasdaqGM:KYMR Stok Raporu

Piyasa değeri: US$3.0b

Kymera Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Kymera Therapeutics CEO'su Nello Mainolfi, Jun2019 tarihinde atandı, in görev süresi 5.42 yıldır. in toplam yıllık tazminatı $ 9.67M olup, şirket hissesi ve opsiyonları dahil olmak üzere 6.6% maaş ve 93.4% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1% ine doğrudan sahiptir ve bu hisseler $ 30.20M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.5 yıl ve 3.9 yıldır.

Anahtar bilgiler

Nello Mainolfi

İcra Kurulu Başkanı

US$9.7m

Toplam tazminat

CEO maaş yüzdesi6.6%
CEO görev süresi5.4yrs
CEO sahipliği1.0%
Yönetim ortalama görev süresi3.5yrs
Yönetim Kurulu ortalama görev süresi3.9yrs

Son yönetim güncellemeleri

Shareholders Will Probably Hold Off On Increasing Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) CEO Compensation For The Time Being

Jun 12
Shareholders Will Probably Hold Off On Increasing Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) CEO Compensation For The Time Being

Recent updates

Earnings Update: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Nov 04
Earnings Update: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Kymera's Protein Degradation Technology: A Promising Bet For Long-Term Biotech Investors

Oct 06

Analysts Are Upgrading Kymera Therapeutics, Inc. (NASDAQ:KYMR) After Its Latest Results

Aug 11
Analysts Are Upgrading Kymera Therapeutics, Inc. (NASDAQ:KYMR) After Its Latest Results

Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) 27% Share Price Surge Not Quite Adding Up

Jul 14
Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) 27% Share Price Surge Not Quite Adding Up

Shareholders Will Probably Hold Off On Increasing Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) CEO Compensation For The Time Being

Jun 12
Shareholders Will Probably Hold Off On Increasing Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) CEO Compensation For The Time Being

We Think Kymera Therapeutics (NASDAQ:KYMR) Can Easily Afford To Drive Business Growth

May 03
We Think Kymera Therapeutics (NASDAQ:KYMR) Can Easily Afford To Drive Business Growth

Kymera Therapeutics: Advancing Into Phase 2 With Partner Sanofi - I Still Have Faith

Mar 21

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Released Earnings Last Week And Analysts Lifted Their Price Target To US$47.43

Feb 25
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Released Earnings Last Week And Analysts Lifted Their Price Target To US$47.43

Optimistic Investors Push Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Up 39% But Growth Is Lacking

Feb 17
Optimistic Investors Push Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Up 39% But Growth Is Lacking

Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Shares Climb 33% But Its Business Is Yet to Catch Up

Dec 29
Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Shares Climb 33% But Its Business Is Yet to Catch Up

We Think Kymera Therapeutics (NASDAQ:KYMR) Needs To Drive Business Growth Carefully

Nov 06
We Think Kymera Therapeutics (NASDAQ:KYMR) Needs To Drive Business Growth Carefully

Industry Analysts Just Made A Substantial Upgrade To Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Revenue Forecasts

Aug 31
Industry Analysts Just Made A Substantial Upgrade To Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Revenue Forecasts

Here's Why We're Not Too Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation

Aug 04
Here's Why We're Not Too Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation

Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Share Price Not Quite Adding Up

May 21
Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Share Price Not Quite Adding Up

We're Hopeful That Kymera Therapeutics (NASDAQ:KYMR) Will Use Its Cash Wisely

Apr 16
We're Hopeful That Kymera Therapeutics (NASDAQ:KYMR) Will Use Its Cash Wisely

Companies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growth

Dec 28
Companies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growth

CEO Tazminat Analizi

Nello Mainolfi'un ücretlendirmesi Kymera Therapeutics'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

-US$167m

Jun 30 2024n/an/a

-US$158m

Mar 31 2024n/an/a

-US$155m

Dec 31 2023US$10mUS$640k

-US$147m

Sep 30 2023n/an/a

-US$167m

Jun 30 2023n/an/a

-US$158m

Mar 31 2023n/an/a

-US$159m

Dec 31 2022US$7mUS$600k

-US$155m

Sep 30 2022n/an/a

-US$154m

Jun 30 2022n/an/a

-US$139m

Mar 31 2022n/an/a

-US$124m

Dec 31 2021US$12mUS$571k

-US$100m

Sep 30 2021n/an/a

-US$79m

Jun 30 2021n/an/a

-US$58m

Mar 31 2021n/an/a

-US$48m

Dec 31 2020US$4mUS$454k

-US$55m

Sep 30 2020n/an/a

-US$53m

Jun 30 2020n/an/a

-US$57m

Mar 31 2020n/an/a

-US$52m

Dec 31 2019US$2mUS$362k

-US$41m

Tazminat ve Piyasa: Nello 'nin toplam tazminatı ($USD 9.67M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 6.65M ).

Tazminat ve Kazançlar: Nello şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.


CEO

Nello Mainolfi (45 yo)

5.4yrs

Görev süresi

US$9,670,542

Tazminat

Dr. Nello Mainolfi, M.D., Ph D., is Co-Founder, President, Chief Executive Officer and Director at Kymera Therapeutics, Inc. since November 2019. Previously, at Kymera Therapeutics, Dr. Mainolfi served as...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Bruce Booth
Co-Founder & Independent Chairman9.2yrsUS$266.46k0%
$ 0
Nello Mainolfi
Co-Founder5.4yrsUS$9.67m1%
$ 30.2m
Bruce Jacobs
Chief Financial Officer5.3yrsUS$4.16m0.18%
$ 5.4m
Jeremy Chadwick
Chief Operating Officer1.5yrsUS$5.19m0.0089%
$ 267.6k
Ellen Chiniara
Chief Legal Officer & Corporate Secretary1.8yrsUS$4.97m0.0094%
$ 282.6k
Jared Gollob
Chief Medical Officer6.2yrsUS$3.47m0.084%
$ 2.5m
Karen Weisbach
Head of People & Culture2.5yrsVeri yokVeri yok
Juliet Williams
Head of Research3.5yrsVeri yokVeri yok

3.5yrs

Ortalama Görev Süresi

59yo

Ortalama Yaş

Deneyimli Yönetim: KYMR 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.5 yıldır).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Bruce Booth
Co-Founder & Independent Chairman9.2yrsUS$266.46k0%
$ 0
Nello Mainolfi
Co-Founder5yrsUS$9.67m1%
$ 30.2m
John M. Maraganore
Independent Director2.8yrsUS$236.46k0%
$ 0
Felix Baker
Lead Independent Directorless than a yearVeri yokVeri yok
Elena Ridloff
Independent Director3.7yrsUS$246.46k0%
$ 0
Leigh Morgan
Independent Director2.3yrsUS$246.46k0%
$ 0
Jeffrey Albers
Independent Director4.3yrsUS$241.46k0%
$ 0
Pamela Esposito
Independent Director4.2yrsUS$243.96k0%
$ 0
Victor Sandor
Independent Director2yrsUS$231.46k0%
$ 0
Gorjan Hrustanovic
Independent Director4.7yrsUS$236.46k0%
$ 0

3.9yrs

Ortalama Görev Süresi

51.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: KYMR 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.9 yıldır).